Patents Issued in January 30, 2020
-
Publication number: 20200030383Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.Type: ApplicationFiled: September 25, 2019Publication date: January 30, 2020Applicant: Janssen Biotech, Inc.Inventor: Jean Xu
-
Publication number: 20200030384Abstract: The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/progenitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.Type: ApplicationFiled: October 1, 2019Publication date: January 30, 2020Applicant: Fred Hutchinson Cancer Research CenterInventors: Irwin D. Bernstein, Colleen Delaney
-
Publication number: 20200030385Abstract: A water resistant enhanced wound healing film includes components by mass volume concentration of: 5-10 mg/L of ultra-fine eggshell powder, 50-500 mg/L of ultramicroshell membrane powder or shell membrane soluble protein, 5-30 mg/L of lysozyme, 5-10 mg/L of chitosan, 0.05-5 mg/L of glycerin, and 0.1-5 mg/L of polymer polysaccharide. Also, a preparation method of the water resistant enhanced wound healing film is disclosed. The whole raw materials of the present invention are non-toxic and have good biocompatibility; the raw materials include eggshell, shell membrane and soluble mixed protein thereof, and lysozyme in residual egg white. In the present invention, various components of the eggshell waste are sufficiently used. The wound healing film has good water resistance, mechanical properties, antibacterial activity and protein absorption capacity, and low degradation rate.Type: ApplicationFiled: October 29, 2018Publication date: January 30, 2020Inventors: Xi Huang, Xiaoyun Li, Meihu Ma, Zhaoxia Cai, Xing Fu
-
Publication number: 20200030386Abstract: The composition having hydrolyzed collagen and Manuka honey includes hydrolyzed collagen in an amount ranging from between 5% to 95% by weight and Manuka honey in an amount ranging from between 5% to not greater than 50% by weight in water. The Manuka honey can have a methylglyoxal concentration greater than 100 mg/kg, and preferably greater than 550 mg/kg.Type: ApplicationFiled: October 7, 2019Publication date: January 30, 2020Inventor: George D. PETITO
-
Publication number: 20200030387Abstract: The present invention relates to a novel use of a bacterial secretome in the field of the treatment of skin lesions and more particularly of wound healing. The invention also relates to cosmetic or dermatological compositions comprising such a bacterial secretome as active agent.Type: ApplicationFiled: April 6, 2018Publication date: January 30, 2020Applicant: PIERRE FABRE DERMO-COSMETIQUEInventors: Nathalie CASTEX-RIZZI, Marie Florence GALLIANO, Hélène HERNANDEZ-PIGEON
-
Publication number: 20200030388Abstract: The present invention pertains to a composition comprising garcinol individually or in combination with forskolin for modifying the gut microbial diversity. More specifically, the invention relates to the use of composition comprising garcinol and forskolin for decreasing the Firmicutes/Bacteroidetes ratio and increasing the count of beneficial microbe, Akkermansia muciniphila.Type: ApplicationFiled: September 30, 2019Publication date: January 30, 2020Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
-
Publication number: 20200030389Abstract: Provided herein are pharmaceutical compositions related to a Blautia strain useful as a therapeutic agent.Type: ApplicationFiled: October 7, 2019Publication date: January 30, 2020Inventors: Brian Goodman, Holly Ponichtera, Andrea Itano, Taylor A. Cormack, Maria Sizova, Valeria Kravitz, Ekaterina Gavrish, Carolina Baez-giangreco
-
Publication number: 20200030390Abstract: Described are microorganisms which are able to suppress the production of malodorous compounds by axillary bacteria. Also described are compositions comprising such microorganisms as well as the use of such micoorganisms in cosmetic, prophylactic or therapeutic applications.Type: ApplicationFiled: February 28, 2019Publication date: January 30, 2020Inventors: ANDREAS REINDL, Rolf Knöll, Christine Lang, Markus Veen, Eckhard Budde, Mewes Boettner
-
Publication number: 20200030391Abstract: The invention relates to the expression of two molecules in viral vectors AAV/IGF2-HA and AAV/IGF2, the associated method and use thereof in the amelioration of protein misfolding-related diseases, such as Huntington's disease, as presented in the in vivo models in FIG. 11/19.Type: ApplicationFiled: December 21, 2017Publication date: January 30, 2020Inventors: Claudio Andrés HETZ FLORES, Paula HUERTA GARCIA
-
Publication number: 20200030392Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.Type: ApplicationFiled: March 7, 2018Publication date: January 30, 2020Inventors: CINDY FEVRE, HÉLÈNE BLOIS, MATHIEU MEDINA
-
Publication number: 20200030393Abstract: A nutritional supplement containing fungal biomass having at least 100 mg/kg iron and processes for producing the nutritional supplement using filamentous fungi are described.Type: ApplicationFiled: August 30, 2019Publication date: January 30, 2020Inventors: J. Bruce WICKING, Yilin BIAN
-
Publication number: 20200030394Abstract: The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of hyaluronic acid from and/or in the cornea, and methods of using the compositions to treat the eye.Type: ApplicationFiled: July 23, 2019Publication date: January 30, 2020Inventors: Wen-Hwa Ting Li, Khalid Mahmood, Ramine Parsa, Manpreet Randhawa, Mingqi Bai, Kenneth T. Holeva
-
Publication number: 20200030395Abstract: The present invention relates to a probiotics composition containing: lactic acid bacteria powder comprising lactic acid bacteria selected from the group consisting of Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, and Lactobacillus rhamnosus; a mushroom extract; and a fructooligosaccharide.Type: ApplicationFiled: February 16, 2017Publication date: January 30, 2020Inventors: Dae Hee LEE, Jae Kang LEE
-
Publication number: 20200030396Abstract: A composition comprising a grape seed extract and a black tea extract. The composition can increase testosterone secretion more effectively than a single component, and can be used for preparing pharmaceutical compositions, foods, health foods, dietary supplements or drinks used for promoting testosterone secretion.Type: ApplicationFiled: April 3, 2018Publication date: January 30, 2020Inventors: Yung-Hsiang LIN, I-Hui CHEN, Kai-Wen KAN, Fu Chen LIU, Ciao-Ting CHEN
-
Publication number: 20200030397Abstract: A method of harvesting trichomes from a cannabis plant piece containing one or more trichomes attached to biomass material, the biomass material including one or more of stalk material, flower material, and leaf material, including freezing a cannabis plant piece by exposing the plant piece to a cryogenic fluid to create a frozen plant piece; processing the frozen plant piece to separate the trichomes from the biomass material using one or more screens; removing the biomass that has been prevented from passing through the one or more screens; and collecting the trichomes that have passed through the one or more screens.Type: ApplicationFiled: July 18, 2019Publication date: January 30, 2020Applicant: Air Products and Chemicals, Inc.Inventors: Michael Robert Himes, Eric Charles Bender, Mark Wayne Lanham, Andrew Vincent Shlanta
-
Publication number: 20200030398Abstract: The present invention relates to methods of skin care or treating dermal conditions characterized by itching, skin redness, skin roughness, keratosis and squama, the method comprising: applying a composition for topical administration comprising a therapeutically effective amount of Kalanchoe daigremontiana extract or juice to an affected area. The compositions are therapeutically effective for hydrating and conditioning the skin and are shown to be clinically effective at treating dermal conditions or skin disorders, in particular, psoriasis, atopic dermatitis or allergic contact dermatitis.Type: ApplicationFiled: October 8, 2019Publication date: January 30, 2020Inventor: Sylwia Nowak
-
Publication number: 20200030399Abstract: An herbal pharmaceutical compositions of California poppy and methods for the treatment of sleep disorders and dream-related disorders is disclosed. The formulation may be in the form of capsules, tablets, caplets or other oral dosage forms and comprises preferably 600 to 2400 mg of a ratio of 4-10 parts (wt) dried plant material to 1 part (wt) aqueous alcohol (50-90 vol % ethanol) extract that is equivalent to 3-12 grams of the dried herb top of California poppy and contain at least 0.8 wt % isoquinoline alkaloids. The composition may further comprise isoquinoline alkaloids whose composition contains Californidine, Escholtzine and Protopine. California poppy can also be used as a therapy for managing people that have sleep and dream disorders such as Post Traumatic Stress syndrome and similar conditions that induce nightmares as well as people using tranquilizer, antidepressant, antipsychotic, sedative, hypnotic and analgesic drugs.Type: ApplicationFiled: February 13, 2018Publication date: January 30, 2020Inventor: Guy Chamberland
-
Publication number: 20200030400Abstract: This invention relates to the use of an Aronia berry extract or a composition comprising said extract for enhancing the reaction time, attention, concentration and psychomotor control of a mammal, more in particular a human. The composition comprising the Aronia extract is formulated for oral ingestion.Type: ApplicationFiled: February 9, 2018Publication date: January 30, 2020Inventors: Antonie Johannes Van der Saag, Mandy Lambrix, Yala Stevens
-
Publication number: 20200030401Abstract: The present invention discloses an anticancer pharmaceutical composition, comprising the following materials in parts by weight: 0.5-30 parts of fruits/leaves of Rosa roxburghii, 0.5-30 parts of fruits/leaves of Phyllanthus emblica, 0.5-30 parts of peel/seeds of Punica granatum, 0.5-30 parts of honey, 0.5-30 parts of flesh/pericarp of Garcinia mangostana, 0.5-30 parts of coconuts, 0.5-30 parts of pulp/peel of Citrus limon, 0.5-30 parts of raw walnuts, 0.1-5 parts of Rhizoma gastrodiae, 0.1-5 parts of Lucid ganoderma, 0.1-5 parts of seeds/leaves of Moringa oleifera, 0.01-2 parts of Radix ranunculi ternati and 0.01-2 parts of Rhizoma paridis.Type: ApplicationFiled: March 22, 2018Publication date: January 30, 2020Inventors: Shouqian Li, Shouyue Li, Yu Zhou
-
Publication number: 20200030402Abstract: A method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, particularly towards dendritic cells is proposed, provides for using the chopped potato sprouts as plant raw materials are extracted with water, then the aqueous extract is centrifuged, a salt agent is added, and the obtained saline solution is then concentrated using ultrafiltration through a 300-kD filter, then the solution is frozen for 24 hours, thawed, and filtered, and the pellet thus obtained is removed, and the raw peptidoglycan is precipitated from the solution by using an acidic salt agent and is further re-solubilized with alkali, then the alkaline solution is dialyzed against distilled water on a 12 kD filter, and the peptidoglycan having a molecular weight of 500 kD to 17000 kD is purified from the resulting solution using gel permeation chromatography.Type: ApplicationFiled: July 3, 2019Publication date: January 30, 2020Inventors: Ravshan I. ATAULLAKHANOV, Aleksey V. PICHUGIN, Tatyana M. MELNIKOVA, Rakhim M. KHAITOV
-
Publication number: 20200030403Abstract: Wolfberry glycopeptide composition and methods for preparing and using the same, the part with a molecular weight distribution of 1000 Da to 10000 Da of the wolfberry glycopeptide accounts for 50-85% on the HPLC differential refractive index map; and the protein content is 20-35% weight percentage, neutral polysaccharide content is 20-35% weight percentage. Optionally, the uronic acid content is 5-20% weight percentage. The preparation method of the present invention removes part of insoluble impurities by a heating flocculation method, instead of the conventional organic solvent extraction process, and without using any organic solvents in the whole process.Type: ApplicationFiled: July 30, 2018Publication date: January 30, 2020Inventors: Long LU, Yan JIANG, Juan SHEN, Zhigang DING, Yuhua XIANG, Guiqing CHEN, Gengyuan TIAN
-
Publication number: 20200030404Abstract: Methods for treating retinopathy are provided and include administering an effective amount of a polypeptide antagovist of a Na/K ATPase/Src receptor complex to a subject. The retinopathy can include diabetic retinopathy. Methods of decreasing angiogenesis in a retinal vasculature are also provided and include the step of administering, such as by intravitreous injection, a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof.Type: ApplicationFiled: December 30, 2016Publication date: January 30, 2020Inventors: Zijian XIE, Joseph I. SHAPIRO
-
Publication number: 20200030405Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.Type: ApplicationFiled: October 7, 2019Publication date: January 30, 2020Applicant: SEATTLE GENETICS, INC.Inventors: Eric Sievers, Dana Kennedy
-
Publication number: 20200030406Abstract: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosting gall bladder-related disorders using sincalide formulations.Type: ApplicationFiled: October 1, 2019Publication date: January 30, 2020Applicant: BRACCO DIAGNOSTICS INC.Inventors: Edmund C. METCALFE, Jo Anna MONTEFERRANTE, Margaret NEWBORN, Irene KUCHAREWICZ ROPIAK, Ernst SCHRAMM, Gregory W. WHITE, Julius P. ZODDA
-
Publication number: 20200030407Abstract: The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.Type: ApplicationFiled: September 26, 2019Publication date: January 30, 2020Inventors: YUN MO, ANGELIKA FRETZEN, BRIAN CALI, MAHENDRA DEDHIYA
-
Publication number: 20200030408Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.Type: ApplicationFiled: September 30, 2019Publication date: January 30, 2020Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
-
Publication number: 20200030409Abstract: Provided is a LYPD1 inhibitor for promoting vascular endothelial network formation in a biological tissue. Also provided is a medicinal composition, said medicinal composition comprising a LYPD1 inhibitor as an active ingredient, for treating and/or preventing neoangiogenic disorders. Also provided is a method which comprises: (a1) a step for providing a cell population containing first cells expressing LYPD1 and vascular endothelial cells; (a2) a step for treating the cell population obtained in step (a1) with a LYPD1 inhibitor; and (a3) a step for culturing the cell population obtained in step (a2).Type: ApplicationFiled: March 6, 2018Publication date: January 30, 2020Applicant: TOKYO WOMEN'S MEDICAL UNIVERSITYInventors: Katsuhisa Matsuura, Tatsuya Shimizu, Shinako Aoki, Satoru Sakamoto
-
Publication number: 20200030410Abstract: The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor (GM-CSF), sucrose octasulfate or sucralfate and hyaluronic acid for the treatment, pre-emptive treatment or prophylaxis of ulcers, wounds and other injuries to the skin or membranes of the body. Other aspects of the invention are methods of treatment or prevention using the compositions described, as well as an application device for use in the methods provided.Type: ApplicationFiled: March 27, 2019Publication date: January 30, 2020Inventor: Lars Heslet
-
Publication number: 20200030411Abstract: Disclosed herein are methods of treating or preventing an autoimmune skin disorder and/or inflammatory skin disorder, skin tumor and obesity in a subject in need thereof by administering an inhibitor capable of inhibiting the activation of inflammasome NLRP1, NLRP1 mutants, an agent that prevents the secretion of stress responsive secreted factors, known pro-inflammatory cytokines, keratinocytes differentiation markers, inflammasome-dependent cytokines, and growth factors in the skin and an agent that reduces the effect of inflammasome-dependent cytokines. The invention encompasses the use of an activator of NLRP1, such as talabostat, specifically for treating skin tumors. Also enclosed herein are methods of determining the likelihood of a subject in developing an autoimmune skin disorder and/or inflammatory skin disorder comprising detecting NLRP1 mutation in a sample obtained from the subject. An inflammasome sensor NLRP1 mutant and compositions for treatment are also disclosed.Type: ApplicationFiled: September 21, 2017Publication date: January 30, 2020Inventors: Bruno REVERSADE, Franklin ZHONG, Ons MAMAI
-
Publication number: 20200030412Abstract: Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in a subject. In particular, the instant disclosure provide exemplary methods and compositions comprising IL-12 promoted hematopoiesis and increased the recovery of peripheral blood cells and survival in lethally irradiated mice as effectively as a BMCT, indicating that rHuIL-12 therapy can to increase HSC engraftment following HSCT. We identified IL-12R?2 expressing cells in irradiated mouse bone marrow which are potential targets of IL-12. Administration of rMuIL-12 increased the number of IL-12R?2 expressing Lin? cells in mouse bone marrow, indicating that bone marrow HSCs and niche cells are the direct target of rMuIL-12 and that hematopoiesis-promoting activity of rMuIL-12 is mediated by IL-12 receptors on HSCs.Type: ApplicationFiled: March 4, 2019Publication date: January 30, 2020Inventor: Lena A. BASILE
-
Publication number: 20200030413Abstract: Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.Type: ApplicationFiled: October 4, 2017Publication date: January 30, 2020Inventors: Géraldine SIEGFRIED, Abdel-Majid KHATIB, Jean-Luc HOEPFFNER, Serge EVRARD
-
Publication number: 20200030414Abstract: The present invention provides a therapeutic agent for failure-to-thrive or short stature which contains C-type natriuretic peptide (CNP) or a CNP derivative as an active ingredient, reduces adverse reactions, and exhibits excellent efficacy, and a method for treating failure-to-thrive or short stature.Type: ApplicationFiled: January 23, 2018Publication date: January 30, 2020Applicant: Daiichi Sankyo Company, LimitedInventors: Naomi Morozumi, Mayumi Furuya, Toshimasa Jindo, Yasuyuki Abe, Shiuhei Mieda, Akiko Ohno
-
Publication number: 20200030415Abstract: Methods for treating headache, migraine and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.Type: ApplicationFiled: July 5, 2019Publication date: January 30, 2020Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
-
Publication number: 20200030416Abstract: A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.Type: ApplicationFiled: October 1, 2019Publication date: January 30, 2020Inventors: Anirban Sen Gupta, Christa Pawloski
-
Publication number: 20200030417Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.Type: ApplicationFiled: October 4, 2018Publication date: January 30, 2020Applicant: APPLIED MOLECULAR TRANSPORT INC.Inventors: Randall J. Mrsny, Tahir Mahmood
-
Publication number: 20200030418Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.Type: ApplicationFiled: September 3, 2019Publication date: January 30, 2020Inventors: Daniel GARRIDO, J. Bruce GERMAN, Carlito B. LEBRILLA, David A. MILLS
-
Publication number: 20200030419Abstract: Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.Type: ApplicationFiled: October 16, 2019Publication date: January 30, 2020Applicant: Wisconsin Alumni Research FoundationInventors: JAN PETER VAN PIJKEREN, Jee-Hwan Oh
-
Publication number: 20200030420Abstract: The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.Type: ApplicationFiled: July 3, 2019Publication date: January 30, 2020Inventors: Haiyan JIANG, Lei DIAO, Shuanglian LI, Paula COBB
-
Publication number: 20200030421Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.Type: ApplicationFiled: July 2, 2019Publication date: January 30, 2020Inventors: Malcolm K. Brenner, Jack James
-
Publication number: 20200030422Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.Type: ApplicationFiled: April 15, 2019Publication date: January 30, 2020Applicant: CureVac AGInventors: Mariola FOTIN-MLECZEK, Karl-Josef KALLEN, Jan C. SCHMOLLINGER
-
Publication number: 20200030423Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided.Type: ApplicationFiled: July 16, 2019Publication date: January 30, 2020Inventors: Christopher James Nicolai, Semih U. Tareen
-
Publication number: 20200030424Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.Type: ApplicationFiled: October 11, 2019Publication date: January 30, 2020Applicant: Innovative Cellular Therapeutics Co., Ltd.Inventors: Zhao Wu, Zhigang Liu, Lei Xiao, Chengfei Pu, Zhiyuan Cao
-
Publication number: 20200030425Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: ApplicationFiled: October 14, 2019Publication date: January 30, 2020Inventors: John J. ENGELHARDT, Mark J. SELBY, Alan J. KORMAN, Mary Diane FEINGERSH, Brenda L. STEVENS
-
Publication number: 20200030426Abstract: Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.Type: ApplicationFiled: September 29, 2017Publication date: January 30, 2020Inventors: David WEINER, Jian Yan
-
Publication number: 20200030427Abstract: The present description relates to malaria vaccines comprising Plasmodium falciparum (Pf) polypeptide complexes and methods of producing the same. The Pf polypeptides in complexes or in a partially complexed arrangement may comprise two or more of the following polypeptides: PfRipr, PfCyrPa and PfRh5. Drosophila cells and expression vectors are also described.Type: ApplicationFiled: February 23, 2018Publication date: January 30, 2020Inventors: Alan Cowman, Julie Healer, Willem Adriaan De Jongh, Teit Max Moscote Sogaard, Thomas Dan Jorgensen, Vladyslav Soroka
-
Publication number: 20200030428Abstract: Aeromonas hydrophila is a reemerging pathogen of channel catfish (Ictalurus punctatus); recent outbreaks from 2009 to 2014 have caused the loss of more than 12 million pounds of market size catfish in Alabama and Mississippi. Genome sequencing revealed a clonal group of A. hydrophila isolates with unique genetic and phenotypic features that is highly pathogenic in channel catfish. Comparison of the genome sequence of a representative catfish isolate (ML09-119) from this virulent clonal group with lower virulence A. hydrophila isolates revealed four fimbrial proteins unique to strain ML09-119. In this work, we expressed and purified four A. hydrophila fimbrial proteins (FimA, Fim, MrfG, and FimOM) and assessed their ability to protect and stimulate protective immunity in channel catfish fingerlings against A. hydrophila ML09-119 infection for vaccine development. Our results showed catfish immunized with FimA, Fim, FimMrfG, and FimOM exhibited 59.83%, 95.41%, 85.72%, and 75.Type: ApplicationFiled: December 8, 2017Publication date: January 30, 2020Applicant: Mississippi State UniversityInventors: Mark L. Lawrence, Attila Karsi, Hossam Abdelhamed
-
Publication number: 20200030429Abstract: The proposed preparation and methods relate to medicinal microbiology and pharmacology, and relate to preparations exhibiting an immunostimulatory effect, which may be used for the prevention and treatment of oncological diseases. The essence of the preparation and methods consists in a primary component of the preparation including a polyvalent corpuscular antigen, prepared on the basis of Treponema pallidum culture strains. The proposed preparation exhibits an immunostimulatory effect, with a primary influence on components of T-cell immunity. The proposed preparation, in a preventative therapeutic application, is effective with regard to tumors of various histogenesis.Type: ApplicationFiled: July 11, 2016Publication date: January 30, 2020Applicant: LIMITED LIABILITY COMPANY "CANCERNET"Inventors: Eduard Isaakovich MORDUKHOVICH, David Borisovich ZHUKOV, Ilya Vladimirovich DARMOV, Veronika Yuryevna OKHAPKINA
-
Publication number: 20200030430Abstract: Chimeric capsular polysaccharides, conjugates comprising such chimeric capsular polysaccharides, and pharmaceutical compositions thereof. Further aspects include methods for immunising a subject against infection by administration of such polysaccharides, conjugates, or compositions.Type: ApplicationFiled: June 30, 2016Publication date: January 30, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Edmondo CAMPISI, Immaculada MARGARIT Y ROS, Roberto ROSINI
-
Publication number: 20200030431Abstract: Provided herein are methods and compositions comprising a Vibrio cholerae bacterium decorated with a fusion protein comprising an antigenic moiety. Such compositions have an increased antigenicity as compared to the same strain of Vibrio cholerae that is not decorated with the fusion protein.Type: ApplicationFiled: February 26, 2019Publication date: January 30, 2020Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Paula Watnick, Julie Szu Yu Liao
-
Publication number: 20200030432Abstract: The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: March 16, 2018Publication date: January 30, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe